德国拜耳利伐沙班治什么的？

(Rivaroxaban), as the world's first oral direct factor Xa inhibitor, is mainly used to treat venous thrombosis in adults. Compared with traditional anticoagulants, rivaroxaban has accurate efficacy, does not require constant monitoring, has good safety and is easy to use. It is expected to become an alternative drug to heparin and vitamin K antagonists.

In a study on the prevention of deep vein thrombosis after hip replacement in 60 cases, domestic researchers administered rivaroxaban and low-molecular-weight heparin respectively. The results showed that the incidence of DVT in the rivaroxaban group was significantly reduced, and the incidence of bleeding events was significantly lower than that of the low-molecular-weight heparin group. The control of platelet and coagulation levels was equivalent to that of low-molecular-weight heparin. Foreign researchers have studied the use of rivaroxaban and warfarin in the treatment of early intravascular thrombosis and stent implantation in the treatment of acute iliac and femoral vein thrombosis. They have shown that rivaroxaban is equally effective and safe as warfarin.

A domestic meta-analysis of 24 included articles and 40,001 patients showed that 7 new oral anticoagulants are more effective than low-molecular-weight heparin in preventing venous thromboembolism after total hip and knee replacement, and rivaroxaban is more effective in comparing similar drugs. Another meta-analysis study that included 5 RCTs and 4737 patients showed that compared with heparin/low molecular weight heparin + vitamin K antagonist, the rivaroxaban group has a significantly lower recurrence rate in deep vein thrombosis such as pulmonary embolism, and does not increase the risk of major bleeding, death, etc. It can be seen that Bayer's rivaroxaban from Germany has significant efficacy in the treatment of venous thrombosis.

In 1997, Bayer Healthcare entered the Chinese pharmaceutical market and developed prescription drugs, over-the-counter drugs, medical diagnostics, and animal health services. In 2005, Bayer Healthcare achieved sales revenue of €9.4 billion. As a drug owned by Bayer, its launch has also provided certain help for the treatment of many domestic patients.

Recommended hot articles: /newsDetail/86300.html